Logo

SHPH

Shuttle Pharmaceuticals Holdings, Inc.

SHPH

Shuttle Pharmaceuticals Holdings, Inc. • NASDAQ
$1.43 ▲ 5.93% (+0.08)
Market Cap $1.53 M
52w High $25.25
52w Low $1.26
Dividend Yield 0%
P/E -0.42
Volume 39.79K
Outstanding Shares 1.07M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.266M ▼ $-2.347M ▲ 0% $-1.05 ▲ $-2.327M ▲
Q2-2025 $0 $3.91M ▲ $-3.706M ▼ 0% $-3.29 ▼ $-3.91M ▼
Q1-2025 $0 $2.951M ▲ $-3.053M ▼ 0% $-0.75 ▼ $-3.04M ▼
Q4-2024 $0 $1.775M ▼ $-1.598M ▲ 0% $-0.54 ▼ $-1.437M ▲
Q3-2024 $0 $3.052M $-3.784M 0% $-0.37 $-3.511M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.095M ▼ $3.543M ▼ $2.149M ▲ $1.394M ▼
Q2-2025 $4.818M ▲ $5.504M ▲ $1.899M ▼ $3.606M ▲
Q1-2025 $4.513M ▲ $5.31M ▲ $2.025M ▲ $3.285M ▲
Q4-2024 $1.92M ▲ $2.506M ▲ $1.797M ▼ $709.152K ▲
Q3-2024 $156.656K $673.568K $1.989M $-1.315M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.347M ▲ $-2.627M ▲ $0 $-96.375K ▼ $-2.723M ▼ $-2.627M ▲
Q2-2025 $-3.706M ▼ $-3.355M ▼ $0 $3.66M ▼ $305.065K ▼ $-3.355M ▼
Q1-2025 $-3.053M ▼ $-2.527M ▲ $0 $5.119M ▲ $2.592M ▲ $-2.527M ▲
Q4-2024 $-1.598M ▲ $-2.69M ▼ $0 ▼ $4.454M ▲ $1.763M ▲ $-2.69M ▼
Q3-2024 $-3.784M $-1.999M $1.656M $-196.79K $-538.938K $-1.999M

Five-Year Company Overview

Income Statement

Income Statement Shuttle is still purely a research-stage company with no product revenue yet. Its income statement is dominated by research and development and other operating costs, which translate into steady losses. Those losses appear to have increased more recently as clinical and platform work ramped up. This pattern is typical for an early-stage biotech, where the focus is on advancing the pipeline rather than near-term profitability, but it also means the company is far from break-even and financially sensitive to delays or setbacks in trials.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets and cash and no meaningful debt. Equity is also thin, suggesting that past losses have largely absorbed the initial capital base. The absence of debt reduces financial pressure from interest payments, but the limited cash and asset cushion heighten the need for continued access to external funding, such as new equity raises, grants, or partnerships. Overall, the balance sheet reflects a small, capital-constrained biotech that depends heavily on future financing to sustain operations.

Cash Flow

Cash Flow Cash flows from operations are negative, reflecting ongoing spending on research, clinical work, and overhead, with no offsetting inflows from product sales. There is little to no capital spending, so cash burn is almost entirely driven by operating needs. This means the company’s “runway” hinges on its cash balance and its ability to regularly replenish it. Until a partner steps in or a product gets closer to market, investors should expect continued cash outflows and recurring financing needs.

Competitive Edge

Competitive Edge Competitively, Shuttle operates in a narrow but distinctive niche within oncology: improving the effectiveness of radiation therapy. This focus, together with orphan drug status for its lead candidate in glioblastoma and a collection of patents around its molecules and platforms, provides some protection from direct competition. However, it is a very small player in a field dominated by much larger pharmaceutical and biotech companies with deeper pockets and broader pipelines. Its position is therefore a blend of promising scientific differentiation and significant execution and scale risk, especially given reliance on a limited number of key programs.

Innovation and R&D

Innovation and R&D Innovation is the core of Shuttle’s story. The lead candidate, an oral radiation sensitizer for aggressive brain cancer, is in mid-stage clinical testing and benefits from regulatory incentives. Behind it, the company is developing a family of HDAC inhibitors that aim to both attack cancer cells directly and enhance radiation and immune responses, suggesting a multi-pronged approach. The acquisition of an AI-driven discovery platform adds a modern, data-heavy engine that could speed up and sharpen R&D efforts. That said, most of this value is still theoretical: clinical results, regulatory feedback, and the real-world output of the AI platform will determine how much of this R&D promise turns into durable assets.

Summary

Overall, Shuttle is a very early-stage, highly specialized oncology company: no revenue, ongoing losses, and a slim balance sheet, but with an ambitious research agenda centered on making radiation therapy more effective. The scientific and technological story—radiation sensitizers, targeted HDAC inhibitors, and an AI-enabled discovery platform—is compelling on paper and supported by some regulatory advantages. At the same time, the company’s small size, concentrated pipeline, and continuous cash burn create high operational and financial uncertainty. Future outcomes will depend heavily on clinical trial data, regulatory milestones, and the company’s ability to secure stable funding and strong development partners.

NEWS

November 21, 2025 · 9:30 AM UTC

Shuttle Pharmaceuticals Acquires AI Health Platform

Read more

November 3, 2025 · 7:00 AM UTC

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Read more

October 22, 2025 · 10:00 AM UTC

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Read more

October 22, 2025 · 7:00 AM UTC

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Read more

October 21, 2025 · 5:55 PM UTC

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Read more